vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold

Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee

Read more at globenewswire.com